The accumulation of amyloid beta protein (AbP) in the brain causes the cognitive impairment observed in neurodegenerative pathologies such as Alzheimer’s disease. Recent studies have shown that the clinical improvement reflects the mobilization of amyloid. The present study is based on the hypothesis that a rapid removal of AbP from the blood by an extracorporeal purification system could represent an alternative and particularly effective solution for the treatment of patients suffering from neurodegenerative diseases. In this perspective, we started to define the materials and the most appropriate technologies with the aim to achieve a proof of concept regarding the development of a biocompatible polymer membrane capable of selectively removing high levels of AbP in the blood.
Can the ABP-imprinted membranes make regress the amyloid deposition?
CRISTALLINI, CATERINA;BELLOTTI, ELENA;ROSELLINI, ELISABETTA;CASCONE, MARIA GRAZIA;BARBANI, NICCOLETTA
2014-01-01
Abstract
The accumulation of amyloid beta protein (AbP) in the brain causes the cognitive impairment observed in neurodegenerative pathologies such as Alzheimer’s disease. Recent studies have shown that the clinical improvement reflects the mobilization of amyloid. The present study is based on the hypothesis that a rapid removal of AbP from the blood by an extracorporeal purification system could represent an alternative and particularly effective solution for the treatment of patients suffering from neurodegenerative diseases. In this perspective, we started to define the materials and the most appropriate technologies with the aim to achieve a proof of concept regarding the development of a biocompatible polymer membrane capable of selectively removing high levels of AbP in the blood.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
